Alkermes Plc

詳細情報 Alkermes Plc 企業名

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

企業情報

企業コードALKS

会社名Alkermes Plc

上場日Jul 16, 1991

最高経営責任者「CEO」Mr. Richard F. Pops

従業員数1800

証券種類Ordinary Share

決算期末Jul 16

本社所在地Connaught House

都市DUBLIN

証券取引所NASDAQ Global Select Consolidated

国Ireland

郵便番号D04 C5Y6

電話番号35317728000

ウェブサイトhttps://www.alkermes.com/

企業コードALKS

上場日Jul 16, 1991

最高経営責任者「CEO」Mr. Richard F. Pops

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

他の

22.41M

7.31%

データなし

事業別

地域別

事業別USD

会社名

収益

比率

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

他の

22.41M

7.31%

株主

更新時刻: Sat, Aug 16

株主統計

種類

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

11.18%

T. Rowe Price Associates, Inc.

5.97%

State Street Global Advisors (US)

4.97%

Baker Bros. Advisors LP

3.88%

他の

59.62%

株主統計

比率

BlackRock Institutional Trust Company, N.A.

14.37%

The Vanguard Group, Inc.

11.18%

T. Rowe Price Associates, Inc.

5.97%

State Street Global Advisors (US)

4.97%

Baker Bros. Advisors LP

3.88%

他の

59.62%

種類

株主統計

比率

Investment Advisor

53.83%

Investment Advisor/Hedge Fund

29.52%

Hedge Fund

14.46%

Research Firm

3.18%

Pension Fund

1.82%

Individual Investor

1.66%

Sovereign Wealth Fund

1.18%

Private Equity

0.61%

Bank and Trust

0.44%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

770

179.09M

108.49%

-26.85M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

2023Q1

604

167.47M

100.88%

-20.36M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

BlackRock Institutional Trust Company, N.A.

23.98M

14.54%

-541.92K

-2.21%

Mar 31, 2025

The Vanguard Group, Inc.

18.16M

11.01%

-283.51K

-1.54%

Mar 31, 2025

T. Rowe Price Associates, Inc.

11.62M

7.05%

-472.94K

-3.91%

Mar 31, 2025

State Street Global Advisors (US)

8.02M

4.87%

-792.30K

-8.99%

Mar 31, 2025

Baker Bros. Advisors LP

4.48M

2.72%

+301.53K

+7.21%

Mar 31, 2025

Renaissance Technologies LLC

5.74M

3.48%

+260.10K

+4.75%

Mar 31, 2025

RTW Investments L.P.

6.88M

4.17%

-673.14K

-8.91%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.94M

2.39%

+121.05K

+3.17%

Mar 31, 2025

JP Morgan Asset Management

4.13M

2.5%

+3.88M

+1560.15%

Mar 31, 2025

American Century Investment Management, Inc.

3.47M

2.1%

+14.97K

+0.43%

Mar 31, 2025

詳細を見る

28.550USD

Alkermes Plc

28.550

概要

企業名

金融

分析